Requirements of Propofol With Target Controlled Infusions for Supraglottic Airway Devices
- Conditions
- Appropriate AffectComplication of Device Insertion
- Interventions
- Registration Number
- NCT04664595
- Lead Sponsor
- Prince of Songkla University
- Brief Summary
to evaluate and compare the effect-site concentration of propofol with the TCI system for second-generation SGA device insertion between the I-gel™, Supreme™, ProSeal™ and Laryngeal Tube Suction II™.
to determine the hemodynamic changes during insertion of supraglottic devices in patients undergoing elective surgery and any complications after device insertion.
- Detailed Description
The investigators enrolled ASA physical status I-III patients who were 18-70 years old and scheduled for general anesthesia for elective non-cardiac surgery with SGA devices.Adults with a potentially difficult airway (cervical spine disease, Mallampati classification IV, or a mouth opening less than 2.5 cm.), reactive airway disease, signs of respiratory infection or a plan to remain intubated were excluded from the study. The investigators also excluded patients who had a risk of gastric aspiration or morbid obesity (body mass index \> 35 kg/m2).
Patients were randomized into 4 groups (I-gel™, Supreme™, ProSeal™ and Laryngeal Tube Suction II™ SGAs) according to a computer generated randomization list and patients were allocated consecutively. The sample size of each group required 10 patients.
All patients were pre-oxygenated with 100% oxygen. After the administration of 2 µg/ml intravenous fentanyl for 5 minutes, anesthesia was induced with the Schnider pharmacokinetic TCI system. After equilibration of the plasma-site and effect-site concentrations in propofol TCI, 1 of the 4 types of SGA was randomly inserted by two anesthesiologists (resident trainee and staff doctor) who were unaware of the actual plasma concentration of propofol without the use of a muscle relaxant.
The response of each patient determined the effect-site concentration of propofol of the next patient. "No Response" was defined as Laryngeal Mask Airway Insertion Score = 0 and "Response" was defined as Laryngeal Mask Airway Insertion Score ≥ 1. If the insertion of the supraglottic airway device was successful ("No Response"), then the target effect-site concentration was decreased by a step of 0.4 µg/ml. If the insertion failed ("Response"), the target effect-site concentration was increased by the same dose. The patients' responses to LMA insertion was classified by blinded investigators.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- ASA physical status I-III patients.
- Patients 18-70 years old .
- Patients scheduled for general anesthesia for elective non-cardiac surgery with SGA devices.
- Adults with a potentially difficult airway (cervical spine disease, Mallampati classification IV, or a mouth opening less than 2.5 cm.).
- Adults with reactive airway disease.
- Adults with signs of respiratory infection or a plan to remain intubated were excluded from the study.
- Excluded patients who had a risk of gastric aspiration or morbid obesity (body mass index > 35 kg/m2).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group SP Propofol Fresenius The Supreme™ group Group PS Propofol Fresenius The ProSeal™ group Group IG Propofol Fresenius The I-gel™ group Group LT Propofol Fresenius The Laryngeal Tube Suction IITM group
- Primary Outcome Measures
Name Time Method Tolerability of propofol for supragloqtic airway devices insertion 2 years The effect-site concentration of propofol required to insert supraglottic airway devices.
- Secondary Outcome Measures
Name Time Method Blood pressure changes from baseline after insertion of supraglottic devices 2 years
Trial Locations
- Locations (2)
Price of Songkla University
🇹🇭Hat Yai, Songkhla, Thailand
Songklanagarind Hospital
🇹🇭Hat Yai, Songkhla, Thailand